Unknown

Dataset Information

0

A double-blind, randomised, crossover trial of two botulinum toxin type a in patients with spasticity.


ABSTRACT:

Background

Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing these formulations in spasticity treatment. The aim of our study was to compare the efficacy and safety of Prosigne® with Botox® in the treatment of spasticity.

Methodology/principal findings

We performed a double-blind, randomized, crossover study consisting of 57 patients with clinically meaningful spasticity. The patients were assessed at baseline, 4 and 12 weeks after Prosigne® or Botox® administration. The main outcomes were changes in the patients' Modified Ashworth Scale (MAS), Functional Independence Measure (FIM) and Pediatric Evaluation of Disability Inventory (PEDI) scores and adverse effects related to the botulinum toxin. Both of the toxins were significantly effective in relieving the level of spasticity in adults and children. There were no significant differences found between the Prosigne® and Botox® treatments regarding their MAS, FIM and PEDI scores. Likewise, the incidence of adverse effects was similar between the two groups.

Conclusion

Our results suggest that Prosigne® and Botox® are both efficient and comparable with respect to their efficacy and safety for the three month treatment of spasticity.

Trial registration

ClinicalTrials.gov NCT00819065.

SUBMITTER: Guarany FC 

PROVIDER: S-EPMC3585303 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Botulinum toxin type A (btxA) is one of the main treatment choices for patients with spasticity. Prosigne® a new released botulinum toxin serotype A may have the same effectiveness as Botox® in focal dystonia. However, there are no randomized clinical trials comparing these formulations in spasticity treatment. The aim of our study was to compare the efficacy and safety of Prosigne® with Botox® in the treatment of spasticity.<h4>Methodology/principal findings</h4>We performed  ...[more]

Similar Datasets

| S-EPMC7473957 | biostudies-literature
| S-EPMC6215171 | biostudies-literature
| S-EPMC6502046 | biostudies-literature
| S-EPMC3895790 | biostudies-literature
| S-EPMC4172829 | biostudies-literature
| S-EPMC7944432 | biostudies-literature
| S-EPMC4364783 | biostudies-literature
| S-EPMC2696607 | biostudies-other
| S-EPMC8225105 | biostudies-literature
| S-EPMC5688690 | biostudies-literature